Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment

Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment

Immunotherapies and immune checkpoint inhibitors (ICI) represent the latest revolution in oncology. Several studies have reported an association between the use of corticosteroids and poorer outcomes for patients treated with ICIs. However, it has been never established whether corticoid-induced tum...

Full description

Bibliographic Details
Main Authors:	Paul Gougis, Baptiste Abbar, Julie Benzimra, Aurore Vozy, Jean-Philippe Spano, Luca Campedel
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	Diagnostics
Subjects:	immunotherapy immune checkpoint inhibitors COVID-19 pseudoprogression corticosteroids
Online Access:	https://www.mdpi.com/2075-4418/12/8/1933

Similar Items

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021-07-01)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
by: Amrit S. Gonugunta, et al.
Published: (2022-07-01)

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
by: Stefan Schliep, et al.
Published: (2018-01-01)

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
by: Huijie Zhou, et al.
Published: (2023-03-01)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
by: Zhu W, et al.
Published: (2023-09-01)

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
by: Amber J. Giles, et al.
Published: (2018-06-01)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
by: Yusuke Kunimatsu, et al.
Published: (2023-04-01)

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
by: Sang Eun Won, et al.
Published: (2020-01-01)

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
by: Teresa Amaral, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
by: Hans Urban, et al.
Published: (2022-01-01)

Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
by: Sebastian Mönch, et al.
Published: (2023-06-01)

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
by: Daniel Spakowicz, et al.
Published: (2020-05-01)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
by: Randy F. Sweis, et al.
Published: (2018-04-01)

Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01)

Erratum: Tumor response assessment on imaging following immunotherapy
by: Frontiers Production Office
Published: (2023-03-01)

Tumor response assessment on imaging following immunotherapy
by: Antonia M. Berz, et al.
Published: (2022-10-01)

Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
by: Nadiya Hussain, et al.
Published: (2021-01-01)

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
by: Amy Junghyun Lee, et al.
Published: (2021-05-01)

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon
by: Karim Amrane, et al.
Published: (2023-12-01)

A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy
by: Xin Chen, et al.
Published: (2021-06-01)

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
by: Yongbo Xiang, et al.
Published: (2023-07-01)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
by: Eun Young Kim, et al.
Published: (2019-04-01)

Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy
by: Vrankar Martina, et al.
Published: (2018-10-01)

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
by: Wenxiao Jia, et al.
Published: (2019-12-01)

A Case of Pseudoprogression During Atezolizumab Therapy  in Lung Adenocarcinoma
by: Xue WANG, et al.
Published: (2019-06-01)

Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma
by: Zhi-long Wang, et al.
Published: (2020-08-01)

Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors
by: Guoqiang PAN, et al.
Published: (2019-12-01)

Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
by: Yikun Li, et al.
Published: (2024-12-01)

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression
by: Sif Homburg, et al.
Published: (2024-02-01)

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment
by: Cong Wang, et al.
Published: (2021-12-01)

Skin manifestations associated with checkpoint inhibitors
by: Gianluca Nazzaro, et al.
Published: (2022-06-01)

Cardiotoxicity of checkpoint inhibitors: focus on immune side effects
by: Yuri I. Buziashvili, et al.
Published: (2024-04-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
by: CHEN Shuangqing, et al.
Published: (2022-10-01)

Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT
by: Francesca Tutino, et al.
Published: (2023-05-01)

Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy - Detecting Illusive Disease, Defining Response
by: Raymond Yi-Kun Huang, et al.
Published: (2015-02-01)

iRECIST: how to do it
by: Thorsten Persigehl, et al.
Published: (2020-01-01)

Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
by: Stephanie Sanders, et al.
Published: (2020-04-01)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
by: Shazia Nakhoda, et al.
Published: (2022-06-01)

Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors
by: YANG Wenwen, et al.
Published: (2022-05-01)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
by: Kathryn DeCarli, et al.
Published: (2022-08-01)